Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIN-102 in male patients with adrenomyeloneuropathy due to X-linked adrenoleukodystrophy
NL-OMON56243Phase 3Completed
- Sponsor
- Minoryx Therapeutics
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of leriglitazone in adrenomyeloneuropathy (AMN) and adrenoleukodystrophy (ALD) (3 arms), sponsored by Minoryx Therapeutics. Primary endpoints: Change from baseline to Week 96 in total walking distance in the Six-Minute Walk Test and Long-term safety and tolerability of MIN-102. Started Jan 2018; status: completed.
02
Drugs
leriglitazone
03
Conditions
adrenomyeloneuropathy (AMN)adrenoleukodystrophy (ALD)
Beyond the preview
Go deeper on NL-OMON56243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56243.